Genkyotex Stock LIQUIDNET SYSTEMS

Stocks

FR0011790542

Biotechnology & Medical Research

End-of-day quote LIQUIDNET SYSTEMS 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Genkyotex -.--% -
Director TitleAgeSince
Chairman 53 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 52.02M
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +0.74%+9.14%+76.18%+119.90% 25.57B
Weighted average by Cap. +0.75%+8.71%+86.69%+140.75%
Logo Genkyotex
GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease processes, such as fibrosis, inflammation, pain processing, cancer development and neurodegeneration. The Company's pipeline includes GKT831, a NOX inhibitor aimed at primary biliary cholangitis (PBC) and fibrosis; GKT771, a NOX inhibitor mainly aimed at inflammatory pain and angiogenesis, and other NOX inhibitors, which target at central nervous system (CNS), hearing loss and oncology.
Employees
-